Denali Therapeutics Valuation
Is D2NL34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of D2NL34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate D2NL34's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate D2NL34's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for D2NL34?
Key metric: As D2NL34 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is D2NL34's PB Ratio? | |
|---|---|
| PB Ratio | 2.7x |
| Book | US$1.32b |
| Market Cap | US$3.53b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -4.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does D2NL34's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.2x | ||
BLAU3 Blau Farmacêutica | 1.3x | 18.2% | R$2.7b |
BIOM3 Biomm | 3.9x | n/a | R$1.2b |
HYPE3 Hypera | 1.1x | 13.9% | R$12.8b |
RYZB RayzeBio | 6.5x | 2.0% | US$3.7b |
D2NL34 Denali Therapeutics | 2.7x | 25.6% | R$3.5b |
Price-To-Book vs Peers: D2NL34 is good value based on its Price-To-Book Ratio (2.7x) compared to the peer average (3.2x).
Price to Book Ratio vs Industry
How does D2NL34's PB Ratio compare vs other companies in the Global Biotechs Industry?
| 86 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 86 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: D2NL34 is expensive based on its Price-To-Book Ratio (2.7x) compared to the Global Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is D2NL34's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate D2NL34's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Novartis
CHF 183.8b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
N1VS34
CHF 60.30
7D
1.9%
1Y
27.3%
BeiGene
US$20.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
B1GN34
US$45.36
7D
0%
1Y
n/a
Blau Farmacêutica
R$2.7b
A pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States.
BLAU3
R$15.25
7D
0.9%
1Y
-5.0%